EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB

efavirenz, emtricitabine and tenofovir disoproxil fumarate
$1.2156per EA

Strength

600; 200; 300 mg/1; mg/1; mg/1

Manufacturer

Cipla USA Inc.

NDC

69097021002

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

4/22/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA206894

On Market Since

3/30/2021

Pharmacological Classes

Cytochrome P450 2B6 Inducers
Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C9 Inhibitors
Cytochrome P450 3A Inducers
Cytochrome P450 3A4 Inhibitors
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Analog
Non-Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleosides
Nucleosides

Price History

1W

0.0%

1M

-7.3%

3M

-15.1%

6M

-14.9%

1Y

-28.2%

3Y

-75.9%

5Y

-98.4%

All

-98.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.